AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

AbbVie (NYSE: ABBV) today announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments. Data did not ...

Related Keywords

United Kingdom ,Athens ,Attikír ,Greece ,Ludwigshafen ,Rheinland Pfalz ,Germany ,Mariana Cota Stirner ,Venclyxto Sm ,Instagram ,Exchange Commission ,Facebook ,International Myeloma Society Annual Meeting ,Genentech ,Abbvie Deutschland Gmbh Co ,International Myeloma Working Group ,Blood Cancer Press Kit ,Roche Group ,Youtube ,Twitter ,Myeloma Research Foundation ,Linkedin ,International Myeloma Foundation ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Dexamethasone Compared With Pomalidomide ,Subjects With Relapsed ,Refractory Multiple Myeloma ,Myeloma Research ,Understanding Multiple ,Multiple Myeloma ,Product Characteristics ,Abbvie Deutschland Gmbh ,